Inclusion Criteria:  Between 18 and 75 years old, inclusive at the time of signing the informed consent; Diagnosis of type 2 diabetes, according to the criteria of the American Diabetes Association (ADA), and confirmed at the initial eligibility screening; Body Mass Index ≥25 kg/m2; Possesses a smartphone (iPhone or Android only) capable of running the smartphone applications (Apps) used in the study; Has had no change in the last 4 months prior to randomization (3 months prior to initial screening plus 30-day run-in screening period) in antihyperglycemic medications; Has a current HbA1c level >7%, as determined by both screening assessments; Willing to use an FDA approved glucometer for self-monitoring blood glucose throughout the study; Is capable of giving signed informed consent, which includes compliance with the requirements and restrictions listed in the informed consent form (ICF).  Exclusion Criteria  Are unable to understand, consent to, or comply with the study protocol for any reason; Currently taking prandial (mealtime) insulin;  Have self-reported measures, collected during screening interview, that reveal:  An active eating disorder The taking of or planning to take (within the next 6 months):  i. Oral steroids (planned, or within the past 3 months) ii. Chemotherapy (planned, or within the past 6 months) iii. Weight loss medications or iv. Atypical antipsychotic medications  c. A change in antidepressant or anti-anxiety medication within the past 3 months;  d. A history of bariatric surgery or planned bariatric surgery during the study;  e. The current use of marijuana, cocaine, opioid painkillers, or other addictive substances;  f. The current use of tobacco products or use of tobacco products within the past 6 months;  g. The consumption of alcohol above defined thresholds:  i. For women: more than 3 drinks in a single day, or more than 7 drinks per week and ii. For men: more than 4 drinks in a single day, or more than 14 drinks per week  h. An unstable or life-threatening medical illness;  i. Non-resolved, presumed or confirmed COVID-19 diagnosis prior to randomization or during primary study period;  j. For women only: pregnant (or lactating) or having the intention of becoming pregnant during the time frame of the study.  Has a current HbA1c level ≥11%, at the screening assessment; Concurrent enrollment in any other clinical trial; Is considered unreliable by the investigator, or having any condition which, in the opinion of the investigator, would not allow safe participation in the study.